

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 October 2004 (28.10.2004)

PCT

(10) International Publication Number
WO 2004/092118 A2

(51) International Patent Classification⁷: C07C 401/00

(21) International Application Number:
PCT/US2004/011059

(22) International Filing Date: 9 April 2004 (09.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/461,958 10 April 2003 (10.04.2003) US

(71) Applicant (for all designated States except US): WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street, 13th Floor, Madison, WI 53705 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DELUCA, Hector, F. [US/US]; 1809 Highway BB, Deerfield, WI 53531 (US).

SICINSKI, Rafal, R. [PL/PL]; ul. Waszyngtona 33m. 150, PL-04-030 Warsaw (PL). GLEBOCKA, Agnieszka [PL/PL]; Dom Studencki 2, ul. Zwirki i Wigury 95/97, PL-02-089 Warsaw (PL). PLUM, Lori, A. [US/US]; 5339 Brody Drive #204, Madison, WI 53705 (US).

(74) Agents: WOZNY, Thomas, M. et al.; Andrus, Sceales, Starke & Sawall, LLP, 100 East Wisconsin Avenue, Suite 1100, Milwaukee, WI 53202-4178 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: 2-PROPYLIDENE-19-NOR-VITAMIN D COMPOUNDS

VDR Competitive Binding



WO 2004/092118 A2

(57) Abstract: 2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. These compounds also increase both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.



Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*